Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 9, 2003. The report is a disclosure of changes in director interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
- Retirement Fund Holdings: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan increased from 18,707,477 to 18,777,884.
- Transaction Date: The movement in the fund occurred on July 7, 2003.
- Average Price: The shares were acquired at an average price of $40.74.
- Director Interest: Dr. J P Garnier, a company director, is noted as potentially interested in the shares held in the fund in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director interests and does not contain forward-looking statements or risk assessments.
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan (18,777,884 as of July 7, 2003).
- Confirm the average acquisition price of $40.74 for the recent fund movement.
- Note that Dr. J P Garnier's interest is indirect through the discretionary employee fund, not a direct personal holding change.